Average rate of Hb rise in 2 weeks with EPOGEN® use1
![](-/media/Themes/Amgen/Epogen-com/Epogen-com/Image/Desktop/Professionals/About-Epogen/Benefits/benefits-average-rate.gif)
Data from 13 clinical studies involving IV administration of EPOGEN® to 1,010 anemic adult patients on dialysis. Starting doses were 50 to 150 Units/kg TIW. In the 3 largest studies, the median maintenance dose necessary to maintain the Hb between 10 and
12 g/dL was approximately 75 Units/kg TIW.
In clinical studies, more than 95% of patients receiving EPOGEN® for 3 months avoided RBC transfusion.1
A 26-week, placebo-controlled study of 118 patients examined exercise tolerance and patient-reported physical function2,3*
Increase in Hb levels from approximately 7 to 11 g/dL was associated with improved exercise toleranceLIMITATIONS OF USE
- EPOGEN® has not been shown to improve quality of life, fatigue, or patient well-being.
- EPOGEN® is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Scroll down for additional Important Safety Information
![](-/media/Themes/Amgen/Epogen-com/Epogen-com/Image/Desktop/Professionals/About-Epogen/Benefits/benefits-exercise-tolerance.jpg)
Patients treated with EPOGEN® showed improvement in the number of minutes walked during a treadmill stress test,
gaining approximately 1 additional minute walked on the treadmill for every 1 g/dL increase in Hb.
An increase in Hb levels from approximately 7 to 11 g/dL was associated with improved patient-reported physical function
An increase in Hb levels from approximately 7 to 11 g/dL was associated with improved patient-reported physical function
![](-/media/Themes/Amgen/Epogen-com/Epogen-com/Image/Desktop/Professionals/About-Epogen/Benefits/benefits-patient-reported-physical-function.jpg)
*Reanalysis of data from the Canadian Erythropoietin Study Group (CESG), a 26-week, double-blind, placebo-controlled trial of 118 patients on dialysis with anemia of CRF with an average baseline of Hb ~ 7 g/dL. Patients were randomized to receive either EPOGEN® or placebo TIW; study Hb target range was 9.5 to 13.0 g/dL. By the end of the study, average Hb increased to ~11 g/dL in the EPOGEN®-treated patients and remained unchanged in patients receiving placebo.
†SIP and KDQ are validated instruments that evaluate patient-reported outcomes.
†SIP and KDQ are validated instruments that evaluate patient-reported outcomes.
- Four domains from the SIP were used to assess patient-reported physical function: Physical, Home Management, Ambulation, and Body Care and Movement.
EPOGEN® has not been shown to improve quality of life, fatigue, or patient well-being.